Physician profile
Sally Chetrit
NPI 1477704872
$7,668.17
in general payments reported to CMS, 2019-2025
23 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $137 · 2021: $616 · 2022: $696 · 2023: $2,420 · 2024: $1,789 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,152 · Travel and Lodging: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,152.28 |
| Travel and Lodging | $802.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,636.44 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $1,360.99 | 2023-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $660.49 | 2019-2023 | |
| Alcon Vision LLC | $578.02 | 2022-2025 | Tryptyr, Rocklatan, Eysuvis |
| Sun Pharmaceutical Industries INC. | $577.04 | 2020-2025 | Cequa |
| Abbvie INC. | $434.16 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Harrow Eye, LLC | $385.71 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $341.81 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $325.77 | 2024-2025 | Oxervate |
| Genentech USA, INC. | $296.45 | 2023-2025 | Vabysmo, Susvimo |
| Tarsus Pharmaceuticals, INC. | $245.55 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $198.16 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $147.50 | 2019-2021 | |
| Ivantis, INC | $124.37 | 2021 | |
| Allergan, INC. | $78.76 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $68.27 | 2023-2024 | Syfovre |
| Mallinckrodt Hospital Products INC. | $40.53 | 2021 | |
| Sight Sciences, INC. | $39.91 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $37.33 | 2020-2024 | Tecnis Simplicity, Tecnis Iol |
| Thea Pharma INC. | $28.97 | 2023-2025 | Iyuzeh |
| Amgen INC. | $27.82 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Chetrit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.